GlassScriptPhysician profile
Heeyoung Kim
NPI 1629692637
$5,920.82
in general payments reported to CMS, 2019-2025
42 companies · $386 in 2025
The $386 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,804 · 2022: $1,390 · 2023: $1,697 · 2024: $644 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,727.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,060.88 | 2021-2024 | |
| Novo Nordisk INC | $845.59 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $572.37 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $521.12 | 2022-2025 | Trulance, Xifaxan, Plenvu |
| Gilead Sciences, INC. | $310.21 | 2022-2023 | Epclusa |
| Astrazeneca Pharmaceuticals LP | $215.46 | 2021-2024 | Airsupra |
| Eisai INC. | $199.84 | 2021-2022 | |
| Qol Medical, LLC | $167.72 | 2023-2024 | Sucraid, Sucraid |
| Astellas Pharma US INC | $162.66 | 2024-2025 | Veozah |
| Amarin Pharma, INC. | $158.64 | 2021-2022 | |
| Medtronic, INC. | $156.60 | 2023 | Endoflip |
| Takeda Pharmaceuticals U.S.A., INC. | $143.08 | 2021-2024 | Entyvio |
| Intercept Pharmaceuticals, INC. | $142.89 | 2023 | Ocaliva |
| E.R. Squibb & Sons, L.L.C. | $117.96 | 2022 | |
| Lilly USA, LLC | $111.20 | 2021-2024 | Jardiance, Zepbound, Mounjaro |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heeyoung Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.